Fennec Pharmaceuticals Inc (NASDAQ: FENC) Receives Consensus “Buy” Recommendation from Brokerages


Shares of Fennec Pharmaceuticals Inc (NASDAQ: FENC) received an average “Buy” rating from the six analysts who currently cover the company, reports MarketBeat.com. Two research analysts rated the stock with a keep recommendation and four gave the company a buy recommendation. The one-year average price target among brokers who hedged the stock in the past year is $ 12.00.

Several stock analysts recently published reports on the company. The Maxim Group reduced its price target on Fennec Pharmaceuticals from $ 12.00 to $ 10.00 and set a “buy” rating on the stock in a research report published on Wednesday, December 1. Craig Hallum lowered his price target on Fennec Pharmaceuticals from $ 19.00 to $ 14.00 and set a “buy” rating for the company in a research note on Tuesday, November 30. Cantor Fitzgerald downgraded Fennec Pharmaceuticals from an “overweight” rating to a “neutral” rating in a Tuesday November 30th research note. Finally, Zacks investment research reduced Fennec Pharmaceuticals from a “buy” note to a “keep” note in a research note on Tuesday, November 30.

Several large investors have recently bought and sold shares of FENC. Tibra Equities Europe Ltd purchased a new position in shares of Fennec Pharmaceuticals during the second quarter valued at approximately $ 338,000. Millennium Management LLC purchased a new position in Fennec Pharmaceuticals in the second quarter valued at approximately $ 2,951,000. Virtu Financial LLC increased its stake in Fennec Pharmaceuticals by 12.9% in the second quarter. Virtu Financial LLC now owns 13,454 shares of the company valued at $ 98,000 after purchasing an additional 1,537 shares in the last quarter. Harbert Fund Advisors Inc. purchased a new position in Fennec Pharmaceuticals in the second quarter valued at approximately $ 881,000. Finally, Advisor Group Holdings Inc. increased its stake in Fennec Pharmaceuticals by 359.9% in the second quarter. Advisor Group Holdings Inc. now owns 12,370 shares of the company valued at $ 90,000 after purchasing an additional 9,680 shares in the last quarter. Institutional investors hold 46.52% of the company’s shares.

(A d)

It could be the highest grossing event in crypto history. And that only happens once. If you miss it, there is no second chance.

NASDAQ FENC shares traded up $ 0.18 during trading hours on Friday, reaching $ 4.49. 186,802 shares of the stock were traded for an average volume of 118,674. The company has a market cap of $ 116.78 million, a P / E ratio of -7.24 and a beta of 0.07. The company has a quick ratio of 12.90, a current ratio of 12.90, and a debt ratio of 0.26. Fennec Pharmaceuticals has a 52 week low of $ 3.82 and a 52 week high of $ 10.08. The company’s 50-day simple moving average is $ 7.40 and its two-hundred-day simple moving average is $ 7.43.

Fennec Pharmaceuticals (NASDAQ: FENC) last released its quarterly results on Wednesday, November 10. The company reported ($ 0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($ 0.17) by $ 0.01. As a group, sell-side analysts predict that Fennec Pharmaceuticals will post earnings per share of 0.54 for the current fiscal year.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, is developing product candidates for use in the treatment of cancer in the United States. Its lead product candidate is sodium thiosulfate, which has completed the Phase III clinical trial for the prevention of hearing loss or cisplatin-induced ototoxicity in children.

Read more: What is a candlestick chart?

Analyst recommendations for Fennec Pharmaceuticals (NASDAQ: FENC)

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Fennec Pharmaceuticals now?

Before you consider Fennec Pharmaceuticals, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly asking their clients to buy now before the broader market takes hold of … and Fennec Pharmaceuticals was not on the list.

While Fennec Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here


Comments are closed.